Tumor marker-based RecistTM is superior to RECIST as criteria to predict the long-term benefits of targeted therapy in advanced non-small-cell lung cancer with driver gene mutation... by Kai Xiong, Yi Yang, Yanan Yang, Zhengbo Wang, Yun Liu, Hong Duo, Xinya Yuan, Yao Xiao, He Xiao, Xueqin Yang

Get full text